Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate

Bibliography

• Tomson T, Beghi E, Sundqvist A, Johannessen SI. Medical risks in epilepsy: a review with focus on physical injuries, mortality, traffic accidents and their prevention. Epilepsy Res 2004;60:1-16
   PubMed Web of Science ®Google Scholar
• Perucca E. Pharmacoresistance in epilepsy. How should it be defined? CNS Drugs 1998;10:171-9
   Google Scholar
• Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol 2011;10:446-56
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-19
   PubMed Web of Science ®Google Scholar
• Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 2008;70:54-65
   PubMed Web of Science ®Google Scholar
• Kwan P, Arzimanoglou A, Berg AT, Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51:1069-77
   PubMed Web of Science ®Google Scholar
• Berg AT, Levy SR, Testa FM, Remission of epilepsy after two drug failures in children: a prospective study. Ann Neurol 2009;65:510-19
   PubMedGoogle Scholar
• Callaghan B, Schlesinger M, Rodemer W, Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia 2011;52:619-26
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003;2:347-56
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473-81
   PubMed Web of Science ®Google Scholar
• Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 2010;10(1):119-40
   PubMed Web of Science ®Google Scholar
• Chung SS. New treatment option for partial-onset seizures: efficacy and safety of lacosamide. Ther Adv Neurol Disord 2010;3:77-83
   PubMedGoogle Scholar
• Vimpat, SPC, UCB Pharma, Slough, Berkshire, UK. Available from: http://www.medicines.org.uk/emc/medicines/21158
   Google Scholar
• Bialer M, Johannessen SI, Levy RH, Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 2009;83:1-43
   PubMed Web of Science ®Google Scholar
• Stohr T, Kupferberg HJ, Stables JP, Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 2007;74:147-54
   PubMed Web of Science ®Google Scholar
• Errington AC, Stohr T, Heers C, The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008;73:157-69
   PubMed Web of Science ®Google Scholar
• Curia G, Biagini G, Perucca E, Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs 2009;23:555-68
   PubMed Web of Science ®Google Scholar
• Kropeit D, Schiltmeyer B, Cawello W, Bioequivalence of short-time infusions compared to oral administration of SPM 927. Epilepsia 2004;45(Suppl 7):123-4
   Google Scholar
• Rosenfeld W, Biton V, Mameniskiene R, Pharmacokinetics and safety of lacosamide administered as a replacement for adjunctive oral Lacosamide in patients with partial onset seizures. Epilepsia 2005;46(Suppl 8):184
   PubMedGoogle Scholar
• Biton V, Rosenfeld WE, Whitesides J, Intravenous lacosamide in patients with partial onset seizures. Epilepsia 2008;49:418-24
   PubMed Web of Science ®Google Scholar
• Cawello W, Kropeit D, Schiltmeyer B, Food does not affect the pharmacokinetics of SPM 927. Epilepsia 2004;45(Suppl 7):307
   Google Scholar
• Doty P, Rudd GD, Stohr T, Lacosamide. Neurotherapeutics 2007;4:145-8
   PubMed Web of Science ®Google Scholar
• Sattler A, Schaefer M, May TW, Fluctuation of Lacosamide serum concentrations during the day and occurrence of adverse drug reactions – first clinical experience. Epilepsy Res 2011;95(3):207-12
   PubMed Web of Science ®Google Scholar
• Horstmann R, Bonn R, Cawello W, Basic clinical pharmacological investigations of the new antiepileptic drug SPM 927. Epilepsia 2002;43(Suppl 7):188
   Google Scholar
• Kelemen A, Halasz P. Lacosamide for the prevention of partial onset seizures in epileptic adults. Neuropsychol Dis Treat 2010;6:465-71
   PubMed Web of Science ®Google Scholar
• Greenaway C, Ratnaraj N, Sander JW, Patsalos PN. Saliva and serum lacosamide concentrations in patients with epilepsy. Epilepsia 2011;52:258-63
   PubMed Web of Science ®Google Scholar
• Schiltmeyer B, Cawello W, Kropeit D, Pharmacokinetics of the new antiepileptic drug SPM 927 in human subjects with different age and gender. Epilepsia 2004;45(Suppl 7):313
   Google Scholar
• Beyreuther BK, Freitag J, Heers C, Lacosamide: a review of preclinical properties. CNS Drug Rev 2007;13:21-42
   PubMedGoogle Scholar
• Cawello W, Nickel B, Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol 2010;50:459-71
   PubMed Web of Science ®Google Scholar
• Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50(3):443-53
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Biton V, Jatuzis D, Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48:1308-17
   PubMed Web of Science ®Google Scholar
• Jatuzis D, Biton V, Ben-Menachem E, Evaluation of the effect of oral lacosamide on concomitant AED plasma concentrations in patients with partial seizures. Epilepsia 2005;46(Suppl 8):170
   Google Scholar
• Chung S, Sperling MR, Biton V, Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010;51:958-67
   PubMed Web of Science ®Google Scholar
• Chung S, Ben-Menachem E, Sperling MR, Examining the clinical utility of lacosamide: pooled analyses of three phase 2/3 clinical trials. CNS Drugs 2010;24:1041-54
   PubMed Web of Science ®Google Scholar
• Sake JK, Hebert D, Isojarvi J, A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 2010;24:1955-68
   Google Scholar
• Novy J, Patsalos PN, Sander JW, Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav 2011;20:20-23
   PubMed Web of Science ®Google Scholar
• Cuzzola A, Ferlazzo E, Italiano D, Does lacosamide aggravate Lennox-Gastaut syndrome? Report on three consecutive cases. Epilepsy Behav 2010;19:650-1
   PubMed Web of Science ®Google Scholar
• Gavatha M, Ioannou I, Papavasiliou AS. Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy. Epilepsy Behav 2011;20:691-3
   PubMed Web of Science ®Google Scholar
• Guilhoto LM, Loddenkemper T, Gooty VD, Experience with lacosamide in a series of children with drug resistant focal seizures. Pediatr Neurol 2011;44:414-19
   PubMed Web of Science ®Google Scholar
• Kellinghaus C, Berning S, Immisch I, Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand 2011;123:137-41
   PubMed Web of Science ®Google Scholar
• Albers JM, Moddel G, Dittrich R, Intravenous lacosamide-an effective add-on treatment of refractory status epilepticus. Seizure 2011;21:428-30
   Google Scholar
• Rantsch K, Walter U, Wittsrock M, Efficacy of intravenous lacosamide in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Seizure 2011;20(7):529-32
   PubMedGoogle Scholar
• Shiloh-Malawsky Y, Fan Z, Greenwood R, Successful treatment of childhood prolonged status epilepticus with lacosamide. Seizure 2011;20(7):586-8
   PubMedGoogle Scholar
• Koubeissi MZ, Mayor CL, Estephan B, Efficacy and safety of intravenous lacosamide in refractory nonconvulsive status epilepticus. Acta Neurol Scand 2011;123:142-6
   PubMed Web of Science ®Google Scholar
• Chen LL, Haneef Z, Dorsch A, Successful treatment of refractory simple motor status epilepticus with lacosamide and levetiracetam. Seizure 2011;20:263-5
   PubMedGoogle Scholar
• Parkerson KA, Reinsberger C, Chou SH, Lacosamide in the treatment of acute recurrent seizures and periodic epileptiform patterns in critically ill patients. Epilepsy Behav 2011;20:48-51
   PubMed Web of Science ®Google Scholar
• Goodwin H, Hinson HE, Shermock KM, The use of lacosamide in refractory status epilepticus. Neurocrit Care 2011;14:348-53
   PubMed Web of Science ®Google Scholar
• Krause LU, Brodowski KO, Kellinghaus C. Atrioventricular block following lacosamide intoxication. Epilepsy Behav 2011;20:725-7
   PubMed Web of Science ®Google Scholar
• Krauss G, Ben-Menachem E, Mameniskiene R, Intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures. Epilepsia 2010;51:951-7
   PubMed Web of Science ®Google Scholar
• Degiorgio CM. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav 2010;18:322-4
   PubMed Web of Science ®Google Scholar
• Prunetti P, Perucca E. New and forthcoming antiepileptic drugs. Curr Opin Neurol 2011;24:159-64
   PubMed Web of Science ®Google Scholar
• Vimpat PI. Summary of Product Characteristics, Lacosamide, Vimpat, UCB Pharma Ltd, Bath, UK 2011
   Google Scholar
• Bauer S, Rudd D, Mylius V, Lacosamide intoxication in attempted suicide. Epilepsy Behav 2010;17:549-51
   PubMed Web of Science ®Google Scholar
• McMullin M, Dalrymple R. Analysis for lacosamide in human serum by LC/MS/MS and a summary of 8,000 patient values. Ther Drug Monit 2011;33(4):520-1
   Google Scholar
• Patsalos PN, Berry DJ, Bourgeois BFD, Antiepileptic drugs – best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008;49:1239-76
   PubMed Web of Science ®Google Scholar
• Czuczwar P, Wojtak A, Cioczek-Czuczwar A, Retigabine: the newer potential antiepileptic drug. Pharmacol Rep 2010;62(2):211-19
   PubMedGoogle Scholar
• Porter RJ, Nohria V, Rundfeldt C. Retigabine. Neurotherapeutics 2007;4:149-54
   PubMed Web of Science ®Google Scholar
• Tober C, Rundfeldt C, Rostock A, The phenyl carbamic acid ester D-23129 is highly effective in epilepsy models for generalized and focal seizures at nontoxic doses. Abstr Soc Neurosci 1994;20:1641
   Google Scholar
• Dailey JW, Cheong JH, Kh K, Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical response. Neurosci Lett 1995;195:77-80
   PubMed Web of Science ®Google Scholar
• Kapetanovic IM, Rundfeldt C. D23129: a new anticonvulsant compound. CNS Drugs Rev 1996;2:308-21
   Google Scholar
• Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits. Neurosci Lett 2000;282:73-6
   PubMed Web of Science ®Google Scholar
• Rostock A, Tober C, Rundfeldt C, D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 1996;23:211-23
   PubMed Web of Science ®Google Scholar
• Main MJ, Cryan JE, Dupere JR., Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 2000;58:253-62
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 2010;92:89-124
   PubMed Web of Science ®Google Scholar
• Main MJ, Cryan JE, Dupere JR, Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 2000;58:253-62
   PubMed Web of Science ®Google Scholar
• Wuttke TV, Seebohm G, Bail S, The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol 2005;67:1009-17
   PubMed Web of Science ®Google Scholar
• Lang W, Geissendorfer J, Schenzer A, Refinement of the binding site and mode of action of the anticonvulsant retigabine on KCNQ K+ channels. Mol Pharmacol 2009;75:272-80
   PubMedGoogle Scholar
• Wickenden AD, Yu W, Zou A, Retigabine, a novel anticonvulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 2000;58:591-600
   PubMed Web of Science ®Google Scholar
• Tatulian L, Brown DA. Effects of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells. J Physiol 2003;549(Pt 1):57-63
   PubMedGoogle Scholar
• Ferron GM, Paul J, Fruncillo R, Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 2002;42:175-82
   PubMed Web of Science ®Google Scholar
• Hermann R, Ferron GM, Erb K, Effects of age and sex on the disposition of retigabine. Clin Pharmacol Ther 2003;73:61-70
   PubMedGoogle Scholar
• Summary of Product Characteristics, Eslicarbazepine acetate, Zebinix, EISAI. Hatfield, Hertfordshire, UK 2011
   Google Scholar
• Hemple R, Schupke H, McNeilly PJ, Metabolism of retigabine (D-23129), a novel anticonvulsant. Drug Metab Dispos 1999;27:613-22
   PubMedGoogle Scholar
• McNeilly PJ, Torchin CD, Anderson LW, In vitro glucuronidation of D-23129, a new anticonvulsant, by human liver microsomes and liver slices. Xenobiotica 1997;27:431-41
   PubMed Web of Science ®Google Scholar
• Hiller A, Nguyen N, Strassburg CP, Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos 1999;27:605-12
   PubMed Web of Science ®Google Scholar
• Hermann R, Borlak J, Munzel U, The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine. Pharmacogenomics J 2006;6:211-19
   PubMed Web of Science ®Google Scholar
• Mansbach H, Baulac M. Retigabine. In: Shorvon S, Perucca E, Engle J, editors. The Treatment of Epilepsy. 3rd edition. Blackwell Publishing; Chichester: 2009. p. 637-46
   Google Scholar
• Ferron GM, Patat A, Parks V, Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. Br J Clin Pharmacol 2003;56:39-45
   PubMed Web of Science ®Google Scholar
• Ferron GM, Sachdeo R, Pardot A, Pharmacokinetic interaction between valproic acid, topiramate, phenytoin or carbamazepine and retigabine in epileptic patients. Clin Pharm Ther 2001;69:18
   Google Scholar
• Paul J, Ferron GM, Richards L, Retigabine does not alter the pharmacokinetics of a low-dose oral contraceptive in women. Neurology 2001;56(Suppl 3):A335-6
   Google Scholar
• Porter RJ, Partiot A, Sachdeo R, Randomised multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007;68:1197-204
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Lerche H, Gil-Nagel A, Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010;75:1817-24
   PubMed Web of Science ®Google Scholar
• French JA, Abou-Khalil BW, Leroy RF, Randomised, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011;76:1555-63
   PubMed Web of Science ®Google Scholar
• Strengt T, Christoph T, Andersson KE, Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats. J Urol 2004;172(5 Pt):2054-8
   PubMedGoogle Scholar
• Rode F, Svalo J, Sheykhzade M, Functional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladder. Eur J Pharmacol 2010;638:121-7
   PubMed Web of Science ®Google Scholar
• Rauchenzauner M, Luef G. Update on treatment of partial onset epilepsy: role of eslicarbazepine. Neuropsychiatry Dis Treat 2010;6:723-30
   PubMed Web of Science ®Google Scholar
• Brown ME, El-Mallakh RS. Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures. Ther Clin Risk Manag 2010;6:103-9
   PubMed Web of Science ®Google Scholar
• McCormack PL, Robinson DM. Eslicarbazepine acetate. CNS Drugs 2009;23:71-9
   PubMed Web of Science ®Google Scholar
• Ambrosio AF, Soares-da-Silva P, Carvalho CM, Mechanism of action of carbamazepine. Oxcarbazepine, BIA-2-093, and BIA-2-024. Neurochem Res 2002;27:121-30
   PubMed Web of Science ®Google Scholar
• Benes J, Parada A, Figueiredo AA, Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro- 5H-dibenz[b,f]azepine- 5-carboxamide derivatives. J Med Chem 1999;42:2582-7
   PubMed Web of Science ®Google Scholar
• Ambrosio AF, Silva AP, Araujo I, Neurotoxic/neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2-024. Eur J Pharmacol 2000;46:191-201
   Google Scholar
• Ambrosio AF, Silva AP, Malva JO, Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochem Pharmacol 2001;61:1271-5
   PubMed Web of Science ®Google Scholar
• Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics 2007;4:88-96
   PubMed Web of Science ®Google Scholar
• Parada A, Soares-da-Silva P. The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine. Neurochem Int 2002;40:435-40
   PubMed Web of Science ®Google Scholar
• Almeida L, Soares-da-Silva P. Safety, tolerability, and pharmacokinetics profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. Drugs 2003;4:269-84
   Google Scholar
• Almeida L, Soares-da-Silva P. Safety, tolerability, and pharmacokinetics profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J Clin Pharmacol 2004;44:906-18
   PubMed Web of Science ®Google Scholar
• Almeida L, Falcao A, Maia J, Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol 2005;45:1062-6
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 2004;61:1-48
   PubMed Web of Science ®Google Scholar
• Maia J, Vaz-da-Silva M, Almeida L, Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). Drugs R D 2005;6:201-6
   PubMedGoogle Scholar
• Fontes-Ribeiro C, Macedo T, Nunes T, Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: randomized, ope-label, crossover, single-centre study in healthy volunteers. Drugs R D 2008;9:447-54
   PubMedGoogle Scholar
• Fontes-Ribeiro C, Macedo T, Falcao A, Eslicarbazepine acetate (BIA 2-093): relative bioavailability and bioequivalence of 50 mg/ml oral suspension and 200 mg and 800 mg tablet formulations. Drugs R D 2005;6:253-60
   PubMedGoogle Scholar
• Loureiro AI, Fernandes-Lopes C, Bonifacio MJ, Hepatic UDP-glucuronosyltransferase responsible for esclicarbazepine glucuronidation. Drug Metab Dispos 2011; [Epub ahead of print]
   PubMedGoogle Scholar
• Perucca E, Elger C, Halasz P, Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. Epilepsy Res 2011;96:132-9
   PubMed Web of Science ®Google Scholar
• Falcao A, Maia J, Almeida L, Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. Biopharm Drug Dispos 2007;28:249-56
   PubMed Web of Science ®Google Scholar
• van Heininggen PNM, Eve MD, Oosterhuis B, The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther 1991;50:410-19
   PubMedGoogle Scholar
• Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in pediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clin Pharmacokinet 1995;29:341-69
   PubMed Web of Science ®Google Scholar
• Maia J, Almeida L, Falcao A, Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther 2008;46:119-30
   PubMed Web of Science ®Google Scholar
• Rouan MC, Lecaillon JB, Godbillon J, The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol 1994;47:161-7
   PubMed Web of Science ®Google Scholar
• Almeida L, Potgieter JH, Maia J, Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol 2008;64:267-73
   PubMed Web of Science ®Google Scholar
• Fortuna A, Alves G, Falcao A, Binding of licarbazepine enantiomers to mouse and human plasma proteins. Biopharm Drug Dispos 2010;31:362-6
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Elyas AA, Zakrewska JM. Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbamazepine, in patients with trigeminal neuralgia. Eur J Clin Pharmacol 1990;39:413-15
   PubMed Web of Science ®Google Scholar
• Zhang C, Zuo Z, Kwan P, In vitro transport profile of carbamazepine, oxcarbazepine, Eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia 2011;52(10):1894-904
   PubMed Web of Science ®Google Scholar
• Fuseau E, Fabre MA, Falcao A, Population pharmacokinetics of eslicarbazepine acetate in adult patients with refractory partial seizures. Epilepsia 2008;49:432
   Google Scholar
• Zebindex, SPC, 2011
   Google Scholar
• Almeida L, Nunes T, Sicard E, Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. Acta Neurol Scand 2010;121:257-64
   PubMed Web of Science ®Google Scholar
• Nunes T, Sicard E, Almeida L, Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. Curr Med Res Opin 2010;26:1355-62
   PubMed Web of Science ®Google Scholar
• Rocha JF, Vaz-da-Silva M, Almeida L, Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects. Int J Clin Pharmacol Ther 2009;47:255-61
   PubMed Web of Science ®Google Scholar
• Vaz-da-Silva M, Costa R, Soares E, Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Fundam Clin Pharmacol 2009;23:509-14
   PubMedGoogle Scholar
• Vaz-da-Silva M, Almeida L, Falcao A, Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage open-label, multiple-dose, single-period study. Clin Ther 2010;32:179-92
   PubMed Web of Science ®Google Scholar
• Elger C, Halasz P, Maia J, Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009;50:454-63
   PubMed Web of Science ®Google Scholar
• Gil-Nagel A, Lopes-Lima J, Almeida L, Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 2009;120:281-7
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Gabbai AA, Huffnagel A, Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res 2010;89:278-85
   PubMed Web of Science ®Google Scholar
• Elger C, Bialer M, Cramer JA, Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 2007;48:497-504
   PubMed Web of Science ®Google Scholar
• Almeida L, Minciu I, Nunes T, Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy. J Clin Pharmacol 2008;48:966-77
   PubMed Web of Science ®Google Scholar
• Vaz-da-Silva M, Nunes T, Almeida L, Evaluation of eslicarbazepine acetate on cardiac repolarisation in a thorough QT/QTc study. J Clin Pharmacol 2011; [Epub ahead of print]
   Google Scholar
• Physicians' Desk Reference. 5th edition. Medical Economics Co.; Montvale, NJ: 2001
   Google Scholar
• Miles MV, Tang PH, Ryan MA, Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD). Ther Drug Monit 2004;26(3):300-4
   PubMedGoogle Scholar
• Patsalos PN, Bourgeois BFD. The Epilepsy Prescriber's Guide to Antiepileptic Drugs. Cambridge University Press; Cambridge: 2010
   Google Scholar
• Fattore C, Perucca E. Novel medications for epilepsy. Drugs 2011;71:2151-78
   PubMedGoogle Scholar